Chronic phase CML patients posses T cells capable of recognising autologous tumour cells

Leukemia and Lymphoma

Volumn 43, Issue 5, 2002, Pages 943-951

  Müller, Ludmila ^a   Pawelec, Graham ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Autologous DC; Chronic myelogenous leukemia; MLTC; T cells

Indexed keywords

CYTOKINE; LEUKEMIA ANTIGEN;

ACTIVE IMMUNIZATION; ADOPTIVE IMMUNOTHERAPY; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; CANCER IMMUNOTHERAPY; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DENDRITIC CELL; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; IN VITRO STUDY; LEUKEMIA CELL; LYMPHOCYTE CULTURE; MEDICAL DOCUMENTATION; MIXED CELL CULTURE; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TUMOR CELL; TUMOR CELL CULTURE; VACCINATION;

EID: 0036237494     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190290021687     Document Type: Review

References (56)

1. "Progress in human tumour immunology and immunotherapy"
2. "Novel cancer vaccines"
3. "Mechanisms of the graft-versus-leukemia reaction"
4. "Chronic myeloid leukemia as an immunological target"
5. "MHC-unrestricted immune surveillance of leukemia"
6. "Graft-versus-leukemia reactions after bone marrow transplantation"
7. "Consequences of BCR-ABL expression within the hematopoietic stem cell in chronic myeloid leukemia"
8. "Haematopoietic cell transplantation as immunotherapy"
9. "Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplant: Where we now stand"
10. "Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation"
11. "HLA class II restricted T-cell reactivity to a developmentally regulated antigen shared by leukemic cells and CD34+ early progenitor cells"
12. "Adoptive transfer of minor histocompatibility antigen-specific T lymphocytes eradicates leukemia cells without causing graft-versus-host disease"
13. "Recognition of chronic myelogenous leukaemia cells by autologous T lymphocytes primed in vitro against the patient's dendritic cells"
14. "Generation of CML-specific T cells in cytokine-modified autologous mixed lymphocite/tumour cell cultures"
15. "Antitumor activity in vitro in chronic myelogenous leukaemia revealed after treating peripheral cells with cytosine arabinoside"
16. "Autologous MHC-dependent leukaemia-reactive T lymphocytes in a patient with chronic myeloid leukaemia"
17. "Escape mechanisms in tumor immunity: A year 2000 update"
18. "IFN-alpha regulates IL 10 production by CML cells in vitro"
19. "In vitro cytokine-primed leukaemia cells induce in vivo T cell responsiveness in chronic myeloid leukaemia"
20. "The dendritic cell and human cancer vaccines"
21. "Dendritic cells: Development, function and potential use for cancer immunotherapy"
22. "Generation of dendritic cells from patients with chronic myelogenous leukemia"
23. "Generation of dendritic cells expressing bcr-abl from CD34-positive chronic myeloid leukemia precursor cells"
24. "Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia"
25. "Optimizing preparation of normal dendritic cells and bcr-abl+ mature dendritic cells derived from immunomagnetically purified CD14+ cells"
26. "Immunomodulatory dendritic cells generated from nonfractionated bulk peripheral blood mononuclear cell cultures induce growth of cytotoxic T cells against renal cell carcinoma"
27. "Cytokine-induced tumor immunogenicity: From exogenous cytokines to gene therapy"
28. "Synergistic effects of IL-4 and IL-18 on IL-12-dependent IFN-gamma production by dendritic cells"
29. "T-cell priming by type-1 and type-2 polarized dendritic cells: The concept of a third signal"
30. "Bcr/abl+ autologous dendritic cells for vaccination in chronic myeloid leukemia"
31. "GM-CSF can improve the cytogenetic response obtained with interferon-alpha therapy in patients with chronic myelogenous leukemia"
32. "Direct evidence that leukaemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein"
33. "Defensins are dominant HLA-DR-associated self-peptides from CD34(-) peripheral blood mononuclear cells of different tumor patients (plasmacytoma, chronic myeloid leukemia"
34. "Prevalence of antibodies against proteins derived from leukemia cells in patients with chronic myeloid leukemia"
35. "A listing of human tumor antigens recognized by T cells"
36. "BCR/ABL leukemia oncogene fusion peptides selectively bind to certain HLA-DR alleles and can be recognized by T cells found at low frequency in the repertoire of normal donors"
37. "HLA-DR1-restricted bcr-abl (b3a2)-specific CD4+ T lymphocytes respond to dendritic cells pulsed with b3a2 peptide and antigen-presenting cells exposed to b3a2 containing cell lysates"
38. "ABCR-ABL oncoprotein p210b2a2 fusion region sequence is recognized by HLA-DR2a restricted cytotoxic T lymphocytes and presented by HLA-DR matched cells transfected with an Ii(b2a2) construct"
39. "Specific human cellular immunity to bcr-abl oncogene-derived peptides"
40. "CD4(+) cytotoxic T-cell clones specific for bcr-abl b3a2 fusion peptide augment colony formation by chronic myelogenous leukemia cells in a b3a2-specific and HLA-DR-restricted manner"
41. "Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia"
42. "Dendritic cells stimulate the expansion of bcr-abl specific CD8+ T cells with cytotoxic activity against leukemic cells from patients with chronic myeloid leukemia"
43. "Generation of bcr-abl specific cytotoxic T-lymphocytes by using dendritic cells pulsed with bcr-abl (b3a2) peptide: Its applicability for donor leukocyte transfusions in marrow grafted CML patients"
44. "Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses"
45. "Peptides spanning the junctional region of both the abl/bcr and the bcr/abl fusion proteins bind common HLA class I molecules"
46. "MHC class II-restricted tumor antigens and CD4+ T cells play a role in hematological malignancies as well as solid tumors"
47. "Naturally processed tissue-and differentiation stage-specific autologous peptides bound by HLA class I and II molecules of chronic myeloid leukemia blasts"
48. "Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units"
49. "Mutational analysis of N-RAS and GAP-related domain of the neurofibromatosis type 1 gene in chronic myelogenous leukemia"
50. "Oncogene mutation and prognosis in the myelodysplastic syndromes"
51. "Molecular abnormalities in chronic myeloid leukemia: Deregulation of cell growth and apoptosis"
52. "Acquired loss of p53 induces blastic transformation in p210(bcr/abl)-expressing hematopoietic cells: A transgenic study for blast crisis of human CML"
53. "Cancer immunotherapy targeting Wilms' tumor gene WT1 product"
54. "HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide"
55. "SYFPEITHI: Database for MHC ligands and peptide motifs"
56. "Dendritic-cell-peptide immunization provides immunoprotection against bcr-abl-positive leukemia in mice"